<p>Dr. Winston Tan, Medical Oncologist at Mayo Clinic, discusses the recent FDA approval of erdafitinib and enfortumab for second-line treatment of metastatic bladder cancer.</p>

Dr. Winston Tan, Medical Oncologist at Mayo Clinic, discusses the recent FDA approval of erdafitinib and enfortumab for second-line treatment of metastatic bladder cancer.

Cancer Topics - Recent Approvals: Erdafitinib and Enfortumab for Second-Line Treatment of Metastatic Bladder Cancer

ASCO Education: By the Book features engaging discussions between editors and authors from the ASCO Educational Book.  Hear nuanced views on topics featured in Education Sessions at ASCO meetings and deep dives on the approaches shaping modern oncology that have care teams talking.

Medicine

Health & Fitness

ASCO Education: By the Book features engaging discussions between editors and authors from the ASCO Educational Book. Hear nuanced views on topics featured in Education Sessions at ASCO meetings and deep dives on the approaches shaping modern oncology that have care teams talking.

Share Cancer Topics - Recent Approvals: Erdafitinib and Enfortumab for Second-Line Treatment of Metastatic Bladder Cancer

Sign up to save your podcasts

Cancer Topics - Recent Approvals: Erdafitinib and Enfortumab for Second-Line Treatment of Metastatic Bladder Cancer

Cancer Topics - Recent Approvals: Erdafitinib and Enfortumab for Second-Line Treatment of Metastatic Bladder Cancer

More shows like ASCO Education

Exchanges

NEJM This Week

JAMA Clinical Reviews

Journal of Clinical Oncology (JCO) Podcast

JCO Oncology Practice Podcast

ASCO Daily News

GeriPal - A Geriatrics and Palliative Medicine Podcast

The Curbsiders Internal Medicine Podcast

WSJ Minute Briefing

Core IM | Internal Medicine Podcast

ASCO Guidelines

Harrison's PodClass: Internal Medicine Cases and Board Prep

NEJM AI Grand Rounds

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions